---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-113503"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2026-10-05T12:00:15+00:00"
generated_at: "2026-10-12T14:44:25.720280+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rezolute: FDA recommends pre-BLA meeting for ersodetug in congenital HI despite sunRIZE missing primary endpoint

## Summary
- FDA recommended a Type B pre-BLA meeting as a precursor to a BLA for ersodetug in congenital hyperinsulinism, after reviewing data Rezolute submitted in June 2026.
- sunRIZE Phase 3 missed its primary endpoint: finger-stick SMBG hypoglycemia event reductions were not statistically significant vs placebo; key CGM secondary endpoint at Week 24 also not met.
- FDA explicitly did not opine on approvability of ersodetug for congenital HI, noting any determination would only come during a formal BLA review.
- Topline results from the Phase 3 upLIFT study in tumor HI are expected this quarter; Rezolute will then evaluate BLA strategy for potentially both programs.
- sunRIZE open-label extension ongoing with high retention; ersodetug treatment duration ranges ~9 months to over 2 years, with continued glycemic control and reduced background standard of care.

## SEC filing metadata
- accession: 0001104659-26-113503
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2026-10-05T12:00:15+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465926113503/0001104659-26-113503-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465926113503/tm2626976d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-113503
- JSON: https://secwatch.observer/filing/0001104659-26-113503.json
- Plain text: https://secwatch.observer/filing/0001104659-26-113503.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.